RIGL RIGEL PHARMACEUTICALS INC

NEUTRAL Impact: 2/10 DEFA14A
Horizon immediate Filed Apr 3, 2026 Processed 2mo ago SEC 0001034842-26-000024
Proxy solicitation materials
Latest settled — T+20d
RIGL ▲ +7.97% at T+20d
NEUTRAL call ✓ call won +7.97% · α vs SPY -1.01% · entry $27.36 → $29.54
Next anchor: T+60d in 15d
Last close $32.85 (close Jun 12) · +20.07% from $27.36 entry
Entry anchored
Apr 2, 03:59 PM ET
via Databento tick
T+1d
+5.01%
call +5.01% · α +4.94%
$28.73
settled 2mo ago
T+5d
+9.54%
call +9.54% · α +5.40%
$29.97
settled 2mo ago
T+20d
+7.97%
call +7.97% · α -1.01%
$29.54
settled 6w ago
T+60d
call — · α —
in 15d

Price Chart

Loading chart...

Executive Summary

RIGEL PHARMACEUTICALS INC filed a Definitive Additional Materials (DEFA14A) form, which is supplementary proxy solicitation material related to a shareholder vote. The documents provided are primarily technical SEC filing headers and do not contain substantive information about the vote, such as what is being voted on, the outcome, or management's position. This is a routine administrative filing.

Actionable Insight

This is a routine SEC filing with no actionable financial information. Traders should ignore this filing as it does not contain any material information about the company's operations, financials, or strategic direction. Monitor for the release of the full proxy statement for any material information.

Key Facts

  • The filing is a DEFA14A, which is Definitive Additional Materials for a proxy statement.
  • The documents provided are technical SEC headers and a graphic, not the substantive proxy statement content.
  • The filing is routine and administrative in nature.
  • No information about the vote, candidates, or issues is available in the provided documents.

Financial Impact

No financial impact information available.

Risk Factors

  • The provided documents are incomplete and do not contain the actual proxy statement content.
  • There is a risk of misinterpreting this routine filing as a material event.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001034842-26-000024
Document: 0001034842-26-000024-index-headers.html0001034842-26-000024
Document: 0001034842-26-000024-index.html0001034842-26-000024
Document: 0001034842-26-000024.txt0001034842-26-000024
6 reports for RIGL
Performance horizon
33% Hit rate 1 of 3 directional calls best @ T+20▲ +7.12%Apr 21, 2026
Filters
Rows
Reports for RIGL — sortable, filterable
Type Now
Jun 11, 2026
3d ago
Institutional Cluster
NEUTRAL ★ 3/10
$31.15 awaiting T+5awaiting T+5$32.85 (+5.46%)
May 20, 2026
25d ago
8-K
NEUTRAL ★ 2/10
$29.19 $30.05▲ +2.95%▲ +1.35%$32.85 (+12.54%)
May 12, 2026
4w ago
8-K
BULLISH ★ 7/10
$32.13 $28.30▼ −11.92%▼ −10.76%$32.85 (+2.24%)
May 5, 2026
5w ago
8-K
BEARISH ★ 7/10
$26.67 $29.37▼ −10.12%▼ −8.99%$32.85 (−23.17%)
Apr 21, 2026
7w ago
8-K
BEARISH ★ 7/10
$30.47 $29.16▲ +4.30%▲ +4.35%$32.85 (−7.81%)
Apr 3, 2026
10w ago
DEFA14A
NEUTRAL ★ 2/10
$27.36 $29.97▲ +9.54%▲ +5.40%$32.85 (+20.07%)
Showing 6 of 6

US Market Status

Market Closed — Opens in 5h

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access